Previous close | 6.66 |
Open | 6.66 |
Bid | 6.95 x 300 |
Ask | 6.99 x 800 |
Day's range | 6.52 - 7.03 |
52-week range | 4.14 - 9.37 |
Volume | |
Avg. volume | 1,329,146 |
Market cap | 2.753B |
Beta (5Y monthly) | 1.43 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SANTA MONICA, Calif., April 11, 2024--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., today announced it will release its first quarter 2024 financial results before U.S. markets open on Thursday, May 9, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.
SANTA MONICA, Calif., March 14, 2024--GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx of their decision to resign from the Company’s Board of Directors, effective March 14, 2024 and March 22, 2024, respectively.
SANTA MONICA, Calif., February 29, 2024--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on January 10, 2024.